AMPH — Amphastar Pharmaceuticals, Inc. stock price, charts and financials

QT45Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
19.90
-0.32-1.58%
AMPHQT45Amphastar Pharmaceuticals, Inc.·NASDAQ
19.90-1.58%
TA
Loading chart...
Screen all →
Snapshot
Index-P/E11.99EPS (ttm)1.66Insider Own14.00%Shs Outstand44.09MPerf Week-1.24%
Market Cap877.45MForward P/E6.63EPS next Y3.00Insider Trans0.00%Shs Float32.83MPerf Month1.48%
Enterprise Value1.27BPEG-EPS next Q-Inst Own-Short Float12.71%Perf Quarter-12.49%
Income78.00MP/S1.22EPS this Y55.43%Inst Trans-Short Ratio6.88Perf Half Y-28.72%
Sales720.00MP/B1.14EPS next Y16.27%ROA4.81%Short Interest4.17MPerf YTD-25.69%
Book/sh17.53P/C2.98EPS next 5Y-1.18%ROE10.23%52W High31.26 -36.34%Perf Year-6.18%
Cash/sh6.67P/FCF6.50EPS past 3/5Y5.27% 134.54%ROIC6.02%52W Low16.65 19.52%Perf 3Y-67.29%
Dividend Est.-EV/EBITDA6.61Sales past 3/5Y13.00% 15.52%Gross Margin47.34%Volatility3.26% 3.47%Perf 5Y-4.28%
Dividend TTM-EV/Sales1.76EPS Y/Y TTM-45.75%Oper. Margin16.20%ATR (14)0.76Perf 10Y20.10%
Dividend Ex-DateJun 11, 2010Quick Ratio2.82Sales Y/Y TTM-1.64%Profit Margin11.00%RSI (14)51.72Recom2.83
Dividend Gr. 3/5Y-Current Ratio3.85EPS Q/Q-43.24%SMA202.00%Beta0.88Target Price20.50
Payout0.00%Debt/Eq0.82Sales Q/Q0.00%SMA501.69%Rel Volume0.79Prev Close20.22
Employees1,976LT Debt/Eq0.82EarningsAug 06SMA200-13.16%Avg Volume609.56KPrice19.90
IPO DateJun 25, 2014Option/ShortYes / YesEPS/Sales Surpr.-40.44% -1.32%Net Debt/EBITDA2.69Volume481,647Change-1.58%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-29-26DowngradeB of A SecuritiesNeutralUnderperform
Jun-03-26ReiteratedBarclaysEqual Weight$30$20
May-14-26DowngradeWells FargoOverweightEqual Weight$19
May-11-26ReiteratedPiper SandlerNeutral$32$21
May-08-26DowngradeNeedhamBuyHold
Apr-21-26DowngradeJefferiesBuyHold$22
Dec-08-25InitiatedBarclaysEqual Weight$30
Aug-12-25UpgradeNeedhamHoldBuy
May-12-25DowngradeJP MorganOverweightNeutral
Mar-21-25ReiteratedPiper SandlerNeutral$66$32
Latest News
Jul-29-26
Jul-24-26
Jul-22-26
Jul-18-26
Jul-08-26
Jul-02-26
Company

Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue720720732644499438350322295
Cost of Goods Sold Incl. D&A379364358293250238207190188
Gross Profit341356374351249200143132107
Selling, General and Administrative Excl. Other13213095806769656358
Research and Development928674747561676958
Other Operating Expense00-10-10000
Operating Income11714020519710770110-9
Interest Expense2625302721000
Unusual Expense
Non-Operating Income (Expense)119140915-660-1
Net Income Before Taxes10312418916911584560-10
Income Taxes232630322321414-3
Consolidated Net Income78981601389162149-6
Net Income From Continuing Operations78981601389163147-7
Net Income78981601389162149-6
EPS (Recurring)1.712.103.292.851.881.300.031.04-0.12
EPS (Basic, Before Extraordinaries)1.712.103.292.851.881.300.031.04-0.12
EPS (Diluted)1.662.033.062.601.741.250.030.98-0.12
EBITDA19221227724014611230817
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio11.9913.1912.1323.7916.1018.63703.1519.68
Price To Sales Ratio1.241.752.434.612.752.552.702.823.10
Gross Margin47.3649.4451.0954.5049.9045.6640.8640.9936.27
Operating Margin16.2519.4428.0130.5921.4415.983.140.00-3.05
Net Margin10.8313.6121.8621.4318.2414.160.2915.22-2.03
Shares Outstanding454748484948474746
Market Capitalization8951,2591,7822,9691,3731,118945907915
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$32.90$28.37$23.84$19.31$14.78 Close Price0.00K141.93K283.86K425.79K567.72KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Zhou RongSENIOR EVP, PRODUCTION CENTERDec 17 '25Option Exercise11.339,787110,887147,830Dec 18
Zhou RongSENIOR EVP, PRODUCTION CENTERDec 17 '25Sale26.209,787256,379138,043Dec 18
Petersen Floyd F.DirectorDec 12 '25Sale25.922,42662,88871,368Dec 15
Petersen Floyd F.DirectorDec 11 '25Sale25.691,73744,62073,794Dec 15
PRINS RICHARD KDirectorNov 25 '25Sale27.104,179113,25335,183Nov 25
PRINS RICHARD KDirectorNov 25 '25Option Exercise16.694,17969,74839,362Nov 25
Petersen Floyd F.DirectorNov 13 '25Sale26.4916,679441,83775,531Nov 17
Petersen Floyd F.DirectorNov 13 '25Option Exercise16.6916,679278,37392,210Nov 17
Petersen Floyd F.DirectorNov 03 '25Sale25.2750012,63375,531Nov 05
Petersen Floyd F.DirectorOct 01 '25Sale27.2050013,60276,031Oct 02
Petersen Floyd F.DirectorSep 02 '25Sale30.9850015,49276,531Sep 03
Petersen Floyd F.DirectorAug 01 '25Sale20.8350010,41677,031Aug 04
Petersen Floyd F.DirectorJul 02 '25Sale23.4750011,73477,531Jul 03
Zhang Jack Y.CEO & CHIEF SCIENTIFIC OFFICERJun 13 '25Option Exercise13.03200,0002,606,0002,847,659Jun 16
Petersen Floyd F.DirectorJun 02 '25Sale25.6750012,83572,909Jun 04
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.